KRAS and colorectal cancer: We studied the potential of nimotuzumab-PEG6-DM1-Low and nimotuzumab-PEG6-DM1-High to eradicate tumors in vivo using DLD-1 xenograft, a KRAS mutant (G13D) colorectal cancer model.